Inventiva (IVA) Total Non-Current Liabilities (2018 - 2025)
Inventiva (IVA) posted quarterly Total Non-Current Liabilities of $233.6 million for Q4 2025, up 108.4% year-over-year from $112.1 million in Q4 2024, and down 99.84% quarter-over-quarter from $146.5 billion in Q2 2025.
Analysis
Inventiva (IVA) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Inventiva's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $233.6 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 108.4% year-over-year to $233.6 million; the TTM figure through Dec 2025 stood at $233.6 million (up 108.4% YoY), while the FY2025 annual figure was $233.6 million, up 108.4% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $233.6 million, down from $146.5 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $146.5 billion in Q2 2025, with the low at $11.7 million in Q4 2021.
- The 5-year median for Total Non-Current Liabilities is $55.3 million (2023), against an average of $14.8 billion.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities plunged 99.72% in 2023, then surged 193280.48% in 2025.
- Inventiva's Total Non-Current Liabilities stood at $11.7 million in 2021, then soared by 245.99% to $40.6 million in 2022, then jumped by 36.19% to $55.3 million in 2023, then soared by 102.53% to $112.1 million in 2024, then jumped by 108.4% to $233.6 million in 2025.
- Business Quant data shows IVA's Total Non-Current Liabilities at $233.6 million in Q4 2025, $146.5 billion in Q2 2025, and $112.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | 233.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 233.57 Mn |
| Jun 30, 2025 | 146.48 Mn |
| Dec 31, 2024 | 112.08 Mn |
| Jun 30, 2024 | 75.75 Mn |
| Dec 31, 2023 | 55.34 Mn |
| Jun 30, 2023 | 44.31 Mn |
| Dec 31, 2022 | 40.63 Mn |
| Jun 30, 2022 | 15.60 Mn |
| Dec 31, 2021 | 11.74 Mn |
| Jun 30, 2021 | 16.65 Mn |
| Mar 31, 2021 | 16.76 Mn |
| Dec 31, 2020 | 16.45 Mn |
| Jun 30, 2020 | 1.97 Mn |
| Dec 31, 2019 | 1.89 Mn |
| Dec 31, 2018 | 3.58 Mn |